FINANCINGS

Adma Biologics Inc. priced a public offering of 1.2 million shares at $8 each to raise gross proceeds of about $9.8 million.

Assembly Biosciences Inc. generated $75 million from a public offering.

Cellectis SA set terms for a proposed $129 million IPO.

Cidara Therapeutics Inc. filed for a proposed IPO, aiming to raise $69 million.

Concert Pharmaceuticals Inc. filed to raise about $50 million in a follow-on public offering.

Eagle Pharmaceuticals Inc. priced a public offering of approximately 1.32 million common shares at $42 each.

Esperion Therapeutics Inc. priced a $175 million public offering of 1.75 million shares of common stock at $100 each.

Galena Biopharma Inc. closed a public offering of about 24.4 million units at $1.56 per unit, for gross proceeds of $38 million.

Genocea Biosciences Inc. closed a public offering for gross proceeds of $51.7 million.

Kythera Biopharmaceuticals Inc. closed its public offering for gross proceeds of approximately $143.8 million.

Minerva Neurosciences Inc. is raising $31 million in a private placement offering to several institutional investors.

Nanotherapeutics Inc. secured a $28.5 million debt financing from White Oak Global Advisors LLC.

Retrophin Inc. priced a public offering for expected gross proceeds of about $130 million.

Tekmira Pharmaceuticals Corp. filed to sell 6 million common shares at $20 each to net about $112.5 million in a public offering.

Tetraphase Pharmaceuticals Inc. closed its public offering for gross proceeds of $173.1 million.

Xbiotech Inc. set terms for a $76 million IPO in which it will sell 4 million shares at $19 each.

DEALS

Abbvie Inc. entered an agreement with C2N Diagnostics to develop a portfolio of anti-tau antibodies for the treatment of Alzheimer's disease.

Actavis plc said it completed the acquisition of Allergan Inc. in a cash and equity transaction valued at about $70.5 billion.

Cloud Pharmaceuticals Inc. and the University of Florida Department of Medicine are collaborating to rapidly design and develop drugs to inhibit the reproduction of cancer cells.

Evotec AG and Second Genome Inc. will collaborate in small molecule-based discovery and development activities to treat microbiome-mediated diseases.

Genmab A/S has decided not to exercise the co-development right for Humax-TAC-ADC under its agreement with ADC Therapeutics Sarl.

Grifols SA is taking a 45 percent stake in Alkahest Inc. with a $37.5 million investment, plus $12.5 million more to fund development of plasma-based products.

Kite Pharma Inc. is acquiring privately held T-Cell Factory B.V. for $21 million up front.

Nantworks Inc. and Sorrento Therapeutics Inc. have expanded their ongoing collaboration with a deal to discover and develop cancer immunotherapies.

Pulmatrix Inc. completed a reverse merger with Ruthigen Inc.

Vaccinex Inc. entered a collaboration with Five Prime Therapeutics Inc., allowing for the use Vaccinex's Activmab antibody discovery platform.

Valeant Pharmaceuticals International Inc. increased its offer for Salix Pharmaceuticals Ltd. from $158 per share to $173 per share, which would value the deal at about $11.07 billion.

Valneva SE signed an agreement with Jianshun Biosciences Ltd. on its EB66 cell line for human and veterinary vaccines in China.

. . . AND MORE

Aeolus Pharmaceuticals Inc. said the FDA granted orphan drug designation for AEOL 10150 for the treatment of idiopathic pulmonary fibrosis.

A global Dementia Discovery Fund has launched with an initial $100 million to fund preclinical and early stage research in the field.

Immunovaccine Inc. said it plans to list its common shares on the OTCQX marketplace.

Prometic Life Sciences Inc. said it has been selected for inclusion on the S&P/TSX Composite Index.

Samsung Bioepis Co. Ltd. submitted a marketing authorization application for SB2, its Remicade biosimilar candidate, to the EMA.